Study links anti-VEGF use with elevated IOP
SAN FRANCISCO — Anti-VEGF treatment for wet age-related macular degeneration was found to increase IOP in some patients, according to study data released here at the joint meeting of the American Academy of Ophthalmology and Pan-American Association of Ophthalmology.
Researchers at Yale University School of Medicine found that of 116 AMD patients treated with Avastin (bevacizumab, Genentech) and/or Lucentis (ranibizumab, Genentech), four patients (3.45%) had a significant, sustained increase in IOP.
"To our knowledge, ours is the first study to document persistent ocular hypertension following intravitreal bevacizumab injections in patients with no personal or family history of glaucoma or ocular hypertension," Ron A. Adelman, MD, MPH, said.
"We found that sustained, high IOP may occur after only one anti-VEGF injection, but more typically after multiple injections. Patients' [ocular hypertension] may continue over several AMD treatments and may require IOP-lowering therapy."
osnsupersite.com |
